Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−28.02 USD
−62.01 M USD
412.00 K USD
1.67 M
About Talis Biomedical Corporation
Sector
Industry
CEO
Robert J. Kelley
Website
Headquarters
Chicago
Founded
2013
FIGI
BBG00Z0Z98V3
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Chicago, IL.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TLIS is 1.73 USD — it has decreased by −6.11% in the past 24 hours. Watch Talis Biomedical Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Talis Biomedical Corporation stocks are traded under the ticker TLIS.
TLIS stock has risen by 1.62% compared to the previous week, the month change is a 3.44% rise, over the last year Talis Biomedical Corporation has showed a −78.22% decrease.
TLIS reached its all-time high on Feb 12, 2021 with the price of 508.50 USD, and its all-time low was 1.37 USD and was reached on Sep 4, 2024. View more price dynamics on TLIS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TLIS stock is 6.98% volatile and has beta coefficient of 2.42. Track Talis Biomedical Corporation stock price on the chart and check out the list of the most volatile stocks — is Talis Biomedical Corporation there?
Yes, you can track Talis Biomedical Corporation financials in yearly and quarterly reports right on TradingView.
Talis Biomedical Corporation is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
TLIS net income for the last quarter is −8.85 M USD, while the quarter before that showed −13.04 M USD of net income which accounts for 32.11% change. Track more Talis Biomedical Corporation financial stats to get the full picture.
No, TLIS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 99.00 employees. See our rating of the largest employees — is Talis Biomedical Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Talis Biomedical Corporation EBITDA is −48.04 M USD, and current EBITDA margin is −15.78 K%. See more stats in Talis Biomedical Corporation financial statements.
Like other stocks, TLIS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Talis Biomedical Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Talis Biomedical Corporation technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Talis Biomedical Corporation stock shows the sell signal. See more of Talis Biomedical Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.